Showing 5561-5570 of 5909 results for "".
- Topcon Unveils New Maestro Unlimited OCT System at VEE 2019https://modernod.com/news/topcon-to-present-new-solution-for-oct-and-data-management-at-vee-2019/2476407/Topcon showcased several innovative new offerings at the Vision Expo East (VEE) conference in New York City. Topcon unveiled the new Maestro Unlimited, which pairs the Maestro 3D OCT with the new Topcon Harmony, a web-based data management application that provides unlimited device connect
- Compulink Previews New User Interface for its Optometry SMART EHR at Vision Expo Easthttps://modernod.com/news/compulink-previews-new-user-interface-for-its-optometry-smart-ehr-at-vision-expo-east/2476404/Compulink Healthcare Solutions, the creator of Advantage SMART Practice, an all-in-one EHR and practice management solution powered by artificial intelligence (AI), previewed the new user interface for its Eyecare Advantage at Vision Expo this week. Designed by a team of usability experts,
- Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japanhttps://modernod.com/news/aerie-pharmaceuticals-initiates-netarsudil-ophthalmic-solution-phase-2-clinical-trial-in-japan/2476406/Aerie Pharmaceuticals announced the commencement of patient dosing in its phase 2 clinical trial designed in accordance with the requirements of Japan’s PMDA (Pharmaceuticals and Medical Devices Agency) to support potential regulatory submission of netarsudil ophthalmic solution in Japan. Netarsu
- Aerie Pharmaceuticals Initiates Phase 2 Clinical Trial of AR-1105 in Patients with Macular Edema Associated with RVOhttps://modernod.com/news/aerie-pharmaceuticals-initiates-phase-2-clinical-trial-of-ar-1105-in-patients-with-macular-edema-associated-with-rvo/2476401/Aerie Pharmaceuticals announced the commencement of patient dosing in a phase 2 clinical trial of AR-1105, its investigational dexamethasone intravitreal implant, in patients with macular edema due to retinal vein occlusion (RVO). This phase 2 study (AR1105-CS201) will be conducted at appr
- VSP Global Names Steve Baker President of VSP Ventureshttps://modernod.com/news/vsp-global-names-steve-baker-president-of-vsp-ventures/2476398/VSP Global has announced the appointment of Steve Baker, president of Eyefinity, to lead the newly-established VSP Ventures, according to a report in VisionMonday. “Steve’
- VisionCare Announces Regulatory Approval of the CentraSight Treatment Program in Australiahttps://modernod.com/news/visioncare-announces-regulatory-approval-of-the-centrasight-treatment-program-in-australia/2476395/VisionCare announced that the Australian Department of Health Therapeutic Goods Administration has issued a Therapeutic Goods Certificate to the Implantable Miniature Telescope (by Dr. Isaac Lipshitz), approving it for the improvement of visual acuity in patients who are 55 years and older with b
- Nicox Initiates Phase 2 Trial of NCX 4251 in Blepharitishttps://modernod.com/news/nicox-initiates-phase-2-trial-of-ncx-4251-in-blepharitis/2476393/Nicox SA announced the initiation of a phase 2 clinical trial evaluating NCX 4251, its novel patented ophthalmic suspension of fluticasone propionate nanocrystals, being developed as the first targeted topical treatm
- Nicox Signs Agreement for Zerviate in China for Up to €17 Million in Milestone Payments Plus Royaltieshttps://modernod.com/news/nicox-signs-agreement-for-zerviate-in-china-for-up-to-e17-million-in-milestone-payments-plus-royalties/2476381/Nicox SA and Ocumension Therapeutics announced they have entered into an exclusive license agreement for the development and commercialization of Nicox’s product Zerviate (cetirizine ophthalmic solution), 0.24% for the treatment of all
- Ivantis Announces 24-Month Results of Comparative MIGS Clinical Trialhttps://modernod.com/news/ivantis-announces-24-month-results-of-landmark-prospective-randomized-comparative-migs-clinical-trial/2476379/Ivantis, developer of the Hydrus Microstent, announced the 24-month results of the COMPARE study for minimally invasive glaucoma surgery (MIGS). Results from the study were presented by Thomas Samuelson, MD, President of the American Society of Cataract and Refracti
- Glaukos: Study Confirms Long-Term Efficacy and Safety Profile of iStent in Combination with Cataract Surgeryhttps://modernod.com/news/study-confirms-long-term-efficacy-and-safety-profile-of-glaukos-istent-in-combination-with-cataract-surgery/2476375/Glaukos announced that results of an international glaucoma study published in the Journal of Cataract and Refractive Surgery showed use of iStent Trabecular Micro-Bypass Stent during cataract surgery delivered a 38% reduction in mean IOP to 14.7 mmHg after 5 years of follow-up. The